<code id='471C1305A9'></code><style id='471C1305A9'></style>
      • <acronym id='471C1305A9'></acronym>
      <center id='471C1305A9'><center id='471C1305A9'><tfoot id='471C1305A9'></tfoot></center><abbr id='471C1305A9'><dir id='471C1305A9'><tfoot id='471C1305A9'></tfoot><noframes id='471C1305A9'>
      • <optgroup id='471C1305A9'><strike id='471C1305A9'><sup id='471C1305A9'></sup></strike><code id='471C1305A9'></code></optgroup>
        5. <b id='471C1305A9'><label id='471C1305A9'><select id='471C1305A9'><dt id='471C1305A9'><span id='471C1305A9'></span></dt></select></label></b><u id='471C1305A9'></u>
          <i id='471C1305A9'><strike id='471C1305A9'><tt id='471C1305A9'><pre id='471C1305A9'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / explore / explore      
           
     
           
      
          explore 
           
      
           
      
           
       2025-09-28 13:24:37 
   
      
           
      
           
                        
          explore  
          
                                   
                 
                                      author：leisure time   
                                        
                                      
                                      Page View：1983
                                  
                                    
          
                                   
          Alexis Borisy
          Venture capitalist Alexis Borisy																									Vanessa Leroy for STAT
          EQRx is done, sold for its cash.
          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
          advertisement
          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
                      
                              
          
                                 Previous article：

                                
                                          Senate committee scrutinizes Medicare Advantage brokers
                                
                            
          Next article：  
                                      
                                          DIEP, the 'gold standard' of breast reconstruction, is under threat
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles